JP2023093753A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023093753A5 JP2023093753A5 JP2023076083A JP2023076083A JP2023093753A5 JP 2023093753 A5 JP2023093753 A5 JP 2023093753A5 JP 2023076083 A JP2023076083 A JP 2023076083A JP 2023076083 A JP2023076083 A JP 2023076083A JP 2023093753 A5 JP2023093753 A5 JP 2023093753A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- set forth
- amino acid
- acid sequence
- sequence set
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024088870A JP2024109952A (ja) | 2016-11-08 | 2024-05-31 | レプチン受容体をアンタゴナイズする抗原結合性タンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662419062P | 2016-11-08 | 2016-11-08 | |
| US62/419,062 | 2016-11-08 | ||
| JP2021206917A JP2022031969A (ja) | 2016-11-08 | 2021-12-21 | レプチン受容体をアンタゴナイズする抗原結合性タンパク質 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021206917A Division JP2022031969A (ja) | 2016-11-08 | 2021-12-21 | レプチン受容体をアンタゴナイズする抗原結合性タンパク質 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024088870A Division JP2024109952A (ja) | 2016-11-08 | 2024-05-31 | レプチン受容体をアンタゴナイズする抗原結合性タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023093753A JP2023093753A (ja) | 2023-07-04 |
| JP2023093753A5 true JP2023093753A5 (enExample) | 2023-10-06 |
| JP7611292B2 JP7611292B2 (ja) | 2025-01-09 |
Family
ID=60409473
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019523865A Active JP7042816B2 (ja) | 2016-11-08 | 2017-11-08 | レプチン受容体をアンタゴナイズする抗原結合性タンパク質 |
| JP2021206917A Pending JP2022031969A (ja) | 2016-11-08 | 2021-12-21 | レプチン受容体をアンタゴナイズする抗原結合性タンパク質 |
| JP2023076083A Active JP7611292B2 (ja) | 2016-11-08 | 2023-05-02 | レプチン受容体をアンタゴナイズする抗原結合性タンパク質 |
| JP2024088870A Pending JP2024109952A (ja) | 2016-11-08 | 2024-05-31 | レプチン受容体をアンタゴナイズする抗原結合性タンパク質 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019523865A Active JP7042816B2 (ja) | 2016-11-08 | 2017-11-08 | レプチン受容体をアンタゴナイズする抗原結合性タンパク質 |
| JP2021206917A Pending JP2022031969A (ja) | 2016-11-08 | 2021-12-21 | レプチン受容体をアンタゴナイズする抗原結合性タンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024088870A Pending JP2024109952A (ja) | 2016-11-08 | 2024-05-31 | レプチン受容体をアンタゴナイズする抗原結合性タンパク質 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10550192B2 (enExample) |
| EP (2) | EP4613772A3 (enExample) |
| JP (4) | JP7042816B2 (enExample) |
| KR (1) | KR102563568B1 (enExample) |
| CN (1) | CN110167965A (enExample) |
| AU (2) | AU2017359439B2 (enExample) |
| CA (1) | CA3043365A1 (enExample) |
| CL (3) | CL2019001263A1 (enExample) |
| CO (1) | CO2019004672A2 (enExample) |
| DK (1) | DK3538554T3 (enExample) |
| EA (1) | EA201991075A1 (enExample) |
| ES (1) | ES3040144T3 (enExample) |
| FI (1) | FI3538554T3 (enExample) |
| HR (1) | HRP20251165T1 (enExample) |
| HU (1) | HUE073276T2 (enExample) |
| IL (2) | IL266426B (enExample) |
| LT (1) | LT3538554T (enExample) |
| MA (1) | MA45801B1 (enExample) |
| MX (2) | MX2019005397A (enExample) |
| MY (2) | MY191256A (enExample) |
| PH (1) | PH12019500988A1 (enExample) |
| PL (1) | PL3538554T3 (enExample) |
| PT (1) | PT3538554T (enExample) |
| RS (1) | RS67214B1 (enExample) |
| SG (1) | SG10201913470SA (enExample) |
| SI (1) | SI3538554T1 (enExample) |
| SM (1) | SMT202500327T1 (enExample) |
| UA (1) | UA127678C2 (enExample) |
| WO (1) | WO2018089532A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202417497A (zh) | 2015-10-12 | 2024-05-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| US10550192B2 (en) | 2016-11-08 | 2020-02-04 | Regeneron Pharmaceuticals, Inc. | Antigen-binding proteins that antagonize leptin receptor |
| AU2018390811A1 (en) | 2017-12-18 | 2020-07-02 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof |
| PT3773713T (pt) | 2018-04-06 | 2025-07-29 | Regeneron Pharma | Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia |
| WO2020016160A1 (en) * | 2018-07-16 | 2020-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat neurological diseases |
| EP3898672A1 (en) * | 2018-12-18 | 2021-10-27 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, gdf8 and activin a |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| KR20230038524A (ko) * | 2020-07-17 | 2023-03-20 | 스미토모 세이카 가부시키가이샤 | 흡수체 |
| US20220098313A1 (en) * | 2020-09-15 | 2022-03-31 | Regeneron Pharmaceuticals, Inc. | Use of LEPR Agonists for Pain |
| CN118436632B (zh) * | 2024-07-05 | 2024-08-30 | 四川大学华西第二医院 | Teriflunomide在制备预防和/或治疗原发性纤毛不动综合征的药物中的用途 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5856098A (en) | 1994-09-14 | 1999-01-05 | Progenitor, Inc. | Detection of a leptin receptor variant |
| US5912123A (en) | 1994-09-14 | 1999-06-15 | Progenitor, Inc. | Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology |
| US6451523B1 (en) | 1994-09-14 | 2002-09-17 | Interneuron Pharmaceuticals, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
| US5643748A (en) | 1994-09-14 | 1997-07-01 | Progenitor, Inc. | HU-B1.219, a novel human hematopoietin receptor |
| US6482927B1 (en) | 1995-11-27 | 2002-11-19 | Millennium Pharmaceuticals, Inc. | Chimeric proteins comprising the extracellular domain of murine Ob receptor |
| US6977240B1 (en) * | 1995-11-27 | 2005-12-20 | Millenium Pharmaceuticals, Inc. | Methods of using the OB receptor antibodies to treat bodyweight disorders |
| DE69734443T2 (de) | 1996-01-08 | 2006-07-13 | Genentech, Inc., South San Francisco | Ob-rezeptor und liganden |
| US20050019325A1 (en) * | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
| US7063958B1 (en) * | 1996-01-16 | 2006-06-20 | The Rockefeller University | Nucleic acids db, the receptor for leptin |
| AU2476301A (en) | 1996-01-16 | 2001-05-24 | Rockefeller University, The | DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof |
| AU1833197A (en) | 1996-01-18 | 1997-08-11 | Progenitor, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
| ATE320479T1 (de) | 1996-01-23 | 2006-04-15 | Indevus Pharmaceuticals Inc | Process zur verwendung des obese-gens und seines genprodukts zur stimulierung der entwicklung von haemotopoietischen zellen |
| US7067472B1 (en) | 1996-06-04 | 2006-06-27 | The Scripps Research Institute | Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies |
| US5965521A (en) | 1997-02-25 | 1999-10-12 | Eli Lilly Company | Pulsatile delivery of leptin receptor ligands |
| IL120733A0 (en) | 1997-04-29 | 1997-08-14 | Yeda Res & Dev | Leptin as an inhibitor of cell proliferation |
| US6696411B1 (en) | 1998-04-22 | 2004-02-24 | Cornell Research Foundation, Inc. | Canine erythropoietin gene and recombinant protein |
| AU767068B2 (en) | 1999-06-11 | 2003-10-30 | Baylor College Of Medicine | Methods and compositions for control of bone formation via modulation of leptin activity |
| US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
| FR2852397B1 (fr) | 2003-03-10 | 2005-04-29 | Utilisation des genes leprotl 1 et ob-rgrp pour le criblage de composes actifs sur la prise ou la perte de poids ou le diabete d'un sujet humain ou animal. | |
| DE60314412T2 (de) * | 2003-08-21 | 2008-02-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Neuer Leptin-Antagonist |
| DE10353593A1 (de) * | 2003-11-17 | 2005-06-23 | Klinikum der Universität München Großhadern-Innenstadt | Leptinantagonist und Verfahren zur quantitativen Messung von Leptin |
| US7863240B2 (en) | 2004-10-08 | 2011-01-04 | Enzo Therapeutics, Inc. | Methods and uses of leptin in hepatocellular carcinoma |
| US8969291B2 (en) | 2004-10-08 | 2015-03-03 | Enzo Therapeutics, Inc. | Methods for decreasing leptin levels or activity for treating inflammation |
| US7575878B2 (en) | 2004-11-18 | 2009-08-18 | Vib Vzw | Methods of inhibiting leptin-induced signaling with fibronectin III domain antibodies |
| US7307142B2 (en) * | 2004-11-26 | 2007-12-11 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem | Leptin antagonists |
| WO2006116260A2 (en) | 2005-04-26 | 2006-11-02 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
| PE20071101A1 (es) | 2005-08-31 | 2007-12-21 | Amgen Inc | Polipeptidos y anticuerpos |
| WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
| GB0715216D0 (en) | 2007-08-03 | 2007-09-12 | Asterion Ltd | Leptin |
| DK2356270T3 (da) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| JP6013915B2 (ja) | 2010-11-17 | 2016-10-25 | 中外製薬株式会社 | 血液凝固第ｖｉｉｉ因子の機能を代替する機能を有する多重特異性抗原結合分子 |
| EP2672999A2 (en) | 2011-02-10 | 2013-12-18 | Roche Glycart AG | Improved immunotherapy |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| SI2895513T1 (sl) | 2012-09-12 | 2018-11-30 | Genzyme Corporation | Polipeptidi, ki vsebujejo FC, s spremenjeno glikozilacijo in zmanjšano efektorsko funkcijo |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| LT2840892T (lt) * | 2013-02-20 | 2018-07-25 | Regeneron Pharmaceuticals, Inc. | Nežmogaus tipo gyvūnai su modifikuotomis imunoglobulino sunkiųjų grandinių sekomis |
| US20170051062A1 (en) | 2014-02-18 | 2017-02-23 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and Pharmaceutical Compositions for the Treatment of Diseases Mediated by the NRP-1/OBR Complex Signaling Pathway |
| TW202417497A (zh) | 2015-10-12 | 2024-05-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| US10550192B2 (en) | 2016-11-08 | 2020-02-04 | Regeneron Pharmaceuticals, Inc. | Antigen-binding proteins that antagonize leptin receptor |
-
2017
- 2017-11-08 US US15/807,426 patent/US10550192B2/en active Active
- 2017-11-08 HR HRP20251165TT patent/HRP20251165T1/hr unknown
- 2017-11-08 WO PCT/US2017/060690 patent/WO2018089532A1/en not_active Ceased
- 2017-11-08 JP JP2019523865A patent/JP7042816B2/ja active Active
- 2017-11-08 AU AU2017359439A patent/AU2017359439B2/en active Active
- 2017-11-08 MA MA45801A patent/MA45801B1/fr unknown
- 2017-11-08 EP EP25187542.3A patent/EP4613772A3/en active Pending
- 2017-11-08 CA CA3043365A patent/CA3043365A1/en active Pending
- 2017-11-08 FI FIEP17801273.8T patent/FI3538554T3/fi active
- 2017-11-08 PT PT178012738T patent/PT3538554T/pt unknown
- 2017-11-08 SG SG10201913470SA patent/SG10201913470SA/en unknown
- 2017-11-08 RS RS20250925A patent/RS67214B1/sr unknown
- 2017-11-08 MX MX2019005397A patent/MX2019005397A/es unknown
- 2017-11-08 MY MYPI2019002549A patent/MY191256A/en unknown
- 2017-11-08 PL PL17801273.8T patent/PL3538554T3/pl unknown
- 2017-11-08 SM SM20250327T patent/SMT202500327T1/it unknown
- 2017-11-08 LT LTEPPCT/US2017/060690T patent/LT3538554T/lt unknown
- 2017-11-08 HU HUE17801273A patent/HUE073276T2/hu unknown
- 2017-11-08 UA UAA201906354A patent/UA127678C2/uk unknown
- 2017-11-08 ES ES17801273T patent/ES3040144T3/es active Active
- 2017-11-08 EP EP17801273.8A patent/EP3538554B1/en active Active
- 2017-11-08 DK DK17801273.8T patent/DK3538554T3/da active
- 2017-11-08 SI SI201731619T patent/SI3538554T1/sl unknown
- 2017-11-08 KR KR1020197016377A patent/KR102563568B1/ko active Active
- 2017-11-08 EA EA201991075A patent/EA201991075A1/ru unknown
- 2017-11-08 MY MYPI2022002957A patent/MY203682A/en unknown
- 2017-11-08 CN CN201780082335.4A patent/CN110167965A/zh active Pending
-
2019
- 2019-05-02 IL IL266426A patent/IL266426B/en active IP Right Grant
- 2019-05-03 PH PH12019500988A patent/PH12019500988A1/en unknown
- 2019-05-07 CO CONC2019/0004672A patent/CO2019004672A2/es unknown
- 2019-05-08 CL CL2019001263A patent/CL2019001263A1/es unknown
- 2019-05-08 MX MX2023011233A patent/MX2023011233A/es unknown
-
2020
- 2020-01-07 US US16/736,760 patent/US11535675B2/en active Active
- 2020-01-30 IL IL272358A patent/IL272358B/en unknown
- 2020-03-05 CL CL2020000549A patent/CL2020000549A1/es unknown
- 2020-04-16 CL CL2020001023A patent/CL2020001023A1/es unknown
-
2021
- 2021-12-21 JP JP2021206917A patent/JP2022031969A/ja active Pending
-
2022
- 2022-11-17 US US18/056,411 patent/US20230235068A1/en active Pending
-
2023
- 2023-05-02 JP JP2023076083A patent/JP7611292B2/ja active Active
-
2024
- 2024-05-31 JP JP2024088870A patent/JP2024109952A/ja active Pending
-
2025
- 2025-02-28 AU AU2025201454A patent/AU2025201454A1/en active Pending